Download MendeleyDiscovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions.
Heald, R.A., Jackson, P., Savy, P., Jones, M., Gancia, E., Burton, B., Newman, R., Boggs, J., Chan, E., Chan, J., Choo, E., Merchant, M., Rudewicz, P., Ultsch, M., Wiesmann, C., Yue, Q., Belvin, M., Price, S.(2012) J Med Chem 55: 4594-4604
- PubMed: 22506516
- DOI: https://doi.org/10.1021/jm2017094
- Primary Citation of Related Structures:
3V01, 3V04 - PubMed Abstract:
Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered. These series contain an H-bond acceptor, in a shifted position compared with previously disclosed compounds, and an adjacent H-bond donor, resulting in a bidentate interaction with the Ser212 residue of MEK1. The most potent compound identified, 1 (G-894), is orally active in in vivo pharmacodynamic and tumor xenograft models.
Organizational Affiliation:
Argenta, 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, UK. [email protected]
